Ovid Therapeutics, Inc. (OVID)
2.375
-0.10
(-3.85%)
USD |
NASDAQ |
Oct 22, 16:00
2.375
0.00 (0.00%)
After-Hours: 20:00
Ovid Therapeutics Gross Profit Margin (Quarterly) : 97.82% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 97.82% |
| March 31, 2026 | |
| December 31, 2025 | 93.87% |
| September 30, 2025 | 87.12% |
| June 30, 2025 | 98.42% |
| March 31, 2025 | -7.69% |
| December 31, 2024 | -93.42% |
| September 30, 2024 | 2.31% |
| June 30, 2024 | 12.43% |
| March 31, 2024 | 8.11% |
| December 31, 2023 | -183.5% |
| September 30, 2023 | -269.3% |
| Date | Value |
|---|---|
| June 30, 2023 | -426.4% |
| March 31, 2023 | -501.2% |
| December 31, 2022 | -850.3% |
| September 30, 2022 | -3.64K% |
| June 30, 2022 | |
| March 31, 2022 | 0.00% |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -26.98% |
| Return on Assets | -23.00% |
| Return on Invested Capital | -24.41% |
| Profit Margin (Quarterly) | -2.05K% |
| Operating Margin (Quarterly) | -2.14K% |
| Return on Net Operating Assets | -291.1% |